Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $211.35, for a total transaction of $4,227,000.00. Following the completion of the transaction, the director now directly owns 531,717 shares of the company’s stock, valued at approximately $112,378,387.95. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Illumina, Inc. (NASDAQ ILMN) opened at $214.86 on Monday. The firm has a market cap of $31,369.56, a price-to-earnings ratio of 62.82, a PEG ratio of 3.55 and a beta of 0.74. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22. Illumina, Inc. has a twelve month low of $119.37 and a twelve month high of $216.08.
Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.99 by $0.12. The business had revenue of $714.00 million for the quarter, compared to the consensus estimate of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. Illumina’s revenue for the quarter was up 17.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.97 EPS. sell-side analysts forecast that Illumina, Inc. will post 3.75 earnings per share for the current fiscal year.
A number of brokerages have issued reports on ILMN. Argus lifted their target price on shares of Illumina from $205.00 to $235.00 and gave the company a “buy” rating in a research note on Wednesday, September 13th. Leerink Swann reissued an “outperform” rating and set a $225.00 target price (up previously from $207.00) on shares of Illumina in a research note on Tuesday, September 12th. Robert W. Baird raised shares of Illumina from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $184.00 to $228.00 in a research note on Wednesday, October 25th. Wells Fargo & Company reissued a “market perform” rating and set a $205.00 target price (up previously from $200.00) on shares of Illumina in a research note on Wednesday, October 25th. Finally, Bank of America Corporation lifted their target price on shares of Illumina from $215.00 to $240.00 and gave the company a “buy” rating in a research note on Wednesday, October 25th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $200.88.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Moors & Cabot Inc. raised its holdings in Illumina by 7.1% in the 3rd quarter. Moors & Cabot Inc. now owns 7,500 shares of the life sciences company’s stock worth $1,497,000 after acquiring an additional 500 shares during the period. IFM Investors Pty Ltd bought a new position in Illumina in the 3rd quarter worth $804,000. DF Dent & Co. Inc. raised its holdings in Illumina by 4.0% in the 3rd quarter. DF Dent & Co. Inc. now owns 486,530 shares of the life sciences company’s stock worth $96,917,000 after acquiring an additional 18,741 shares during the period. Neuberger Berman Group LLC raised its holdings in Illumina by 10.0% in the 3rd quarter. Neuberger Berman Group LLC now owns 5,384 shares of the life sciences company’s stock worth $1,072,000 after acquiring an additional 491 shares during the period. Finally, Virtu Financial LLC bought a new position in Illumina in the 3rd quarter worth $577,000. Hedge funds and other institutional investors own 90.76% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://transcriptdaily.com/2017/11/27/insider-selling-illumina-inc-ilmn-director-sells-4227000-00-in-stock.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.